Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable.

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

That imatinib 800 mg/d induced remissions more rapidly, when compared with the combination of imatinib with IFN-α, supports the efficacy of high-dose imatinib but does not exclude the possibility of a ...

However, clinical activity of imatinib in DFSP is striking even in DFSP expressing relatively low amounts of activated PDGFRB. 38, 48 In our trials, we have not studied molecular changes during ...

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

Imatinib specifically inhibits the kinase activity of ABL (including BCR-ABL), PDGFRB, and c-KIT. Recently, this compound has shown efficacy in the treatment of chronic myeloid leukemia 7–9 and ...

The FDA first approved imatinib (Gleevec, Novartis), a protein-tyrosine kinase inhibitor, in 2001 under the accelerated approval program for use in adult patients with chronic myelogenous leukemia ...

With imatinib’s recent IND clearance, Tenax expects to start its Phase III registrational study early next year following the active PK study, with trial conclusion and results expected in 4Q:21.

Imatinib has now been used by more than 100,000 patients worldwide, totaling more than 200,000 patient-years of exposure, she noted.

Imatinib (leevec) generic is a protein-tyrosine kinase inhibitor, prescribed for treating certain type of cancers such as chronic myelogenous leukemia (cancer of the white blood cells, acute ...